Operating Income (Annual)

Operating Income: The income after operating expenses.

Verrica Pharmaceuticals Inc. (VRCA) had Operating Income of $-12.19M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$35.58M
Net Income	$-17.89M
Cost of Goods Sold	$3.44M
Gross Profit	$32.14M
Operating Expenses	$47.76M
Operating Income	$-12.19M
Non-Operating Income/Expense	$-5.70M
Pre-Tax Income	$-17.89M
Normalized Pre-Tax Income	$-17.89M
Income after Taxes	$-17.89M
Income from Continuous Operations	$-17.89M
Consolidated Net Income/Loss	$-17.89M
Normalized Income after Taxes	$-17.89M
EBIT	$-12.19M
EBITDA	$-11.40M
Weighted-Average Shares Outstanding (Basic)	10.65M
Weighted-Average Shares Outstanding (Diluted)	10.65M
Earnings per Share (EPS) (Basic)	$-1.68
Earnings per Share (EPS) (Diluted)	$-1.68
Balance Sheet Financials
Current Assets	$42.54M
Property, Plant, and Equipment	$0.21M
Long-Term Assets	$4.59M
Total Assets	$47.13M
Current Liabilities	$16.44M
Long-Term Debt	$0.64M
Long-Term Liabilities	$5.95M
Total Liabilities	$22.39M
Common Equity	$24.74M
Tangible Shareholders Equity	$24.74M
Shareholders Equity	$24.74M
Common Shares Outstanding	17.18M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-17.63M
Cash Flow from Investing Activities	$0.00M
Cash Flow from Financial Activities	$1.45M
Beginning Cash	$46.33M
End Cash	$30.15M
Increase/Decrease in Cash	$-16.18M
Stock-Based Compensation	$3.32M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.59
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.03
Debt to Equity Ratio	0.04
Gross Margin	90.33%
Operating Margin	-34.25%
EBIT Margin	-34.25%
EBITDA Margin	-32.05%
Pre-Tax Profit Margin	-50.27%
Profit Margin	-50.27%
Free Cash Flow	$-17.63M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.75
Inventory Turnover	1.54
Receiveable Turnover	6.59
Days Sales in Receivables	55.37
Return on Equity	-72.29%
Return on Tangible Equity	-72.29%
Return on Assets	-37.95%
Return on Investments	-70.46%
Book Value Per Share	$1.44
Free Cash Flow per Share	$-1.65
Operating Cash Flow per Share	$-1.65

Data from Zacks Investment Research, Inc.